Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 13/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.48 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.48 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.48 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.48 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.48 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.48 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.48 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.48 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.48 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.48 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.48 |
| ▸ | PSMB3 | P49720 | 3/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.48 |
| ▸ | PSMA6 | P60900 | 3/20 | 0.48 |
| ▸ | PSMA8 | Q8TAA3 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957113 | 0.94 | TMPRSS11D (0.52) | OPRK1CTSSPSMB5PSMB11PSMA7 | |
| SCHEMBL18413052 | 0.92 | OPRK1 (0.57) | OPRK1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL13290902 | 0.92 | OPRK1 (0.59) | OPRK1PSMB5PSMB8PSMB9PSMB10 | |
| SCHEMBL11927496 | 0.91 | OPRK1 (0.60) | OPRK1 | |
| SCHEMBL10316406 | 0.90 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL13290894 | 0.90 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL11927490 | 0.89 | REN (0.49) | OPRK1CTSSPSMB5PSMB8REN | |
| SCHEMBL10316470 | 0.87 | OPRK1 (0.55) | OPRK1 | |
| SCHEMBL11927494 | 0.87 | OPRK1 (0.55) | OPRK1 | |
| SCHEMBL18413053 | 0.87 | OPRK1 (0.55) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020056249-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885CTSS 1649/4885PSMB5 4100/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885CTSS 1649/4885PSMB5 4100/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CTSS 329/4885PSMB5 1040/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885CTSS 1649/4885PSMB5 4100/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | OPRK1 1/4885CTSS 1271/4885PSMB5 2240/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885CTSS 516/4885PSMB5 999/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | OPRK1 1/4885CTSS 398/4885PSMB5 2663/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885CTSS 678/4885PSMB5 992/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885CTSS 1649/4885PSMB5 4100/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885CTSS 1271/4885PSMB5 2240/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885CTSS 1271/4885PSMB5 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.